A. Eggermont

Publications870
h-index101
Citations50,802
Highly Influential Citations1,650
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • C. Robert
  • 502 Publications • 52,110 Citations
  • D. Schadendorf
  • 1,269 Publications • 84,724 Citations
  • A. Hauschild
  • 593 Publications • 36,690 Citations
  • R. Dummer
  • 656 Publications • 37,154 Citations
  • Publications
  • Influence
Final version of 2009 AJCC melanoma staging and classification.
PURPOSE To revise the staging system for cutaneous melanoma on the basis of data from an expanded American Joint Committee on Cancer (AJCC) Melanoma Staging Database. METHODS The melanoma staging… Expand
  • 3,992
  • 245
  • PDF
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E… Expand
  • 4,379
  • 110
  • PDF
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Good bacteria help fight cancer Resident gut bacteria can affect patient responses to cancer immunotherapy (see the Perspective by Jobin). Routy et al. show that antibiotic consumption is associated… Expand
  • 1,529
  • 100
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Gut microbes affect immunotherapy The unleashing of antitumor T cell responses has ushered in a new era of cancer treatment. Although these therapies can cause dramatic tumor regressions in some… Expand
  • 1,358
  • 56
  • PDF
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Answer questions and earn CME/CNE
  • 784
  • 41
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the… Expand
  • 559
  • 35
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
BACKGROUND Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety of… Expand
  • 1,085
  • 29
  • PDF
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of innate and T cell–mediated anticancer immune responses. Here we demonstrate that anthracyclines stimulate… Expand
  • 536
  • 25
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Background The programmed death 1 (PD‐1) inhibitor pembrolizumab has been found to prolong progression‐free and overall survival among patients with advanced melanoma. We conducted a phase 3… Expand
  • 629
  • 24
  • PDF
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European… Expand
  • 352
  • 24
...
1
2
3
4
5
...